The Gambling Warning Is Already in the Label. Nobody Asks the Question.

On Tuesday, a group of British psychiatrists, a clinical pharmacist and a medical negligence lawyer sent a letter to the Medicines and Healthcare Products Regulatory Agency asking it to do four things about a family of prescription drugs that can turn patients into compulsive gamblers. The letter names ropinirole, rotigotine, pramipexole and aripiprazole — medications prescribed for Parkinson's disease, restless legs syndrome, bipolar disorder and schizophrenia. Among the signatories are Christopher Fox, professor of clinical psychiatry at Exeter, Ian Maidment, professor of clinical pharmacy at Aston, and Kimberley Davies of Switalskis, the firm that has been contacted by more than 100 patients who say they developed impulse control disorders after starting one of these drugs.

The four asks are modest: discuss the risk when prescribing, review patients regularly for signs of an impulse control disorder, tell patients about lower-risk alternatives, and consider stopping the drug when symptoms appear.

Here is the part of the story that has gone unremarked in the coverage. For three of those four drugs, the American label already says all of it.

What the US labels already require

An impulse control warning is not a rumor in the labeling of these medicines. It is a numbered section, and openFDA serves it verbatim.

Pramipexole, section 5.3, "Impulse Control/Compulsive Behaviors," effective Aug. 31, 2021: "Case reports and the results of cross-sectional studies suggest that patients can experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and/or other intense urges, and the inability to control these urges." The section then instructs prescribers that "because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased gambling urges."

Ropinirole, section 5.6, effective July 6, 2026, carries the same language with one addition: the instruction to specifically ask applies "for Parkinson's disease or RLS."

Aripiprazole, section 5.7, "Pathological Gambling and Other Compulsive Behaviors," effective March 5, 2026: "Post-marketing case reports suggest that patients can experience intense urges, particularly for gambling, and the inability to control these urges while taking aripiprazole." It also tells prescribers to ask specifically, notes that other compulsive urges are reported less frequently — sexual, shopping, binge eating — and closes with a sentence that reads like a liability memo: "Compulsive behaviors may result in harm to the patient and others if not recognized."

So the first, second and fourth of the letter's requests are, in the United States, already the labeled standard of care. Ask the patient. Review for it. Consider stopping. These are not novel regulatory asks in America; they are the printed instructions.

Rotigotine is the exception, and the exception is instructive. The eight rotigotine labels openFDA returns — including the most recent, effective May 27, 2026 — contain no impulse-control or gambling language in section 5 or anywhere else in the document. The drug is a transdermal dopamine agonist in the same family as pramipexole and ropinirole, and it is named in the British letter. Whether that reflects a different evidence base, a different label vintage, or the fact that openFDA's index mixes full labels with repackager versions of them is a question worth putting to the manufacturer rather than a conclusion to draw from a database query. But it means the fourth drug on the letter's list is the one whose American labeling says least about the risk all four are said to share.

The number in the pramipexole label nobody quoted

The pramipexole label also carries the only hard arithmetic in this story, and none of the news coverage used it. In the extended-release trials, "a total of 14 of 387 (4%) treated with pramipexole dihydrochloride extended-release tablets, 12 of 388 (3%) treated with immediate-release pramipexole tablets, and 4 of 281 (1%) treated with placebo reported compulsive behaviors, including pathological gambling, hypersexuality, and/or compulsive buying."

Four percent against one percent. For a behavior that can liquidate a pension in a few months, that is not a rounding error — it is a tripling of a catastrophic outcome, printed in a table that most prescribers will never open because the section above it already told them what to do.

What a 1 percent placebo arm is doing in that table

The placebo column is the most underrated fact here. It establishes that compulsive behavior occurs in this population at baseline — around one in a hundred — which is exactly the wedge a manufacturer needs to argue that a given patient's gambling was going to happen anyway. It is also, read in the other direction, the strongest defense of the drug: the baseline rate means the signal is real and the absolute risk is small. Both readings are correct, and which one a court or a regulator prefers is a matter of framing rather than arithmetic.

The aripiprazole sentence that will be quoted in court

Buried in section 5.7 of the aripiprazole label is a line with no equivalent in the dopamine agonist labels: "It should be noted that impulse-control symptoms can be associated with the underlying disorder."

That is a fair clinical point. Bipolar disorder and schizophrenia both involve impulsivity, and disentangling a medication effect from the illness it treats is genuinely hard. It is also the sentence a defense will read aloud, because it converts an iatrogenic claim into a contested causal one. For restless legs syndrome the differential is trivial — a person without psychiatric illness who starts gambling within days of a first dose has an obvious explanation. For a patient with bipolar disorder, the same behavior has two plausible authors.

This is the asymmetry that makes aripiprazole both the most-prescribed drug on the list and the hardest case to prove. Gaming America reports that roughly 1.8 million Americans are prescribed it each year.

The Mason case was about the switch, not the prescription

The case at the center of the British campaign is more useful than the headline number, because it describes a system failure rather than a single bad decision. Susan Mason was prescribed pramipexole for restless legs syndrome and began spending and gambling more. She raised the concern with her doctor, who switched her to ropinirole. Her gambling intensified. She eventually researched the drugs herself and found the established links. Her doctors admitted it was a breach of duty to prescribe ropinirole after she had reported uncontrollable gambling, and last year she secured a £70,000 settlement — about $93,000.

Read that sequence carefully. The patient did the right thing: she reported the symptom. The clinician did a reasonable-sounding thing: she changed the drug. And the change was worthless, because pramipexole and ropinirole carry functionally identical impulse control warnings under adjacent section numbers. Switching inside the class is not a mitigation; it is a second exposure with the same mechanism.

This is the fourth request in the letter — inform patients of alternative drugs with lower risks — and it is the one that actually requires clinical knowledge rather than a checkbox. For restless legs, the alternatives that avoid dopaminergic agonism are a different class entirely: alpha-2-delta ligands such as gabapentin or pregabalin, or, in some patients, iron repletion. For Parkinson's, the calculus is harder, because the dopamine agonists are doing work that cannot simply be stopped.

2003, 2010, 2016 — and what changed after 2016

The links are not new and have never really been in dispute. Gaming America traces them through a 2003 GSK report on ropinirole and deviant sexual behavior — including a case in which a 63-year-old man taking the drug for Parkinson's assaulted a seven-year-old girl, with the urges subsiding after his dose was reduced — and a 2010 study finding that nearly 20 percent of Parkinson's patients prescribed ropinirole developed impulse control disorders, with problem gambling the most common.

The FDA issued its own safety communication on aripiprazole in 2016, identifying 184 reports of impulse control problems worldwide between November 2002 and January 2016, 164 of them involving gambling. The agency has not issued a comparable communication on the dopamine agonists, whose labels carry the warning without the fanfare.

The denominator is the phone

What has changed since those reports is not the pharmacology. It is access. In 2010, a person gripped by an urge to gamble had to leave the house. In 2026 the same urge is serviced by an app that is already installed, accepts a card already on file, and operates at three in the morning without a single human interaction.

Every estimate of risk in this literature was generated in a lower-access environment than the one patients now live in. A 4 percent incidence rate measured against casino trips is not the same 4 percent measured against a phone, and no one has re-run the numbers.

That is the strongest argument in the British letter, and it is the one the signatories do not quite make: the risk profile of these drugs has not changed, but the exposure has.

What a label cannot do

The gap the letter identifies is real, and it is not an information gap. The information is printed, numbered and served by API. What is missing is a requirement to act on it — a structured question at every visit, a documented answer, a quality measure that a health system gets paid on, a Medication Guide that asks the patient directly rather than instructing the prescriber.

The FDA has instruments for exactly this. It can require a Medication Guide, impose a REMS with Elements to Assure Safe Use, or mandate a registry. For impulse control disorders in dopamine agonists, it has used none of them. The warning exists as an instruction without a verification step, which is the weakest form of safety communication a regulator can issue: it transfers the entire burden of vigilance to a clinician with eleven minutes and a patient who, by the label's own admission, may not recognize what is happening.

For patients and families, the practical version is narrower than any regulatory argument. If someone starts a dopamine agonist or aripiprazole and within days or weeks begins gambling, spending, or behaving sexually in ways that are unrecognizable to them, the label says the prescriber is supposed to ask. It does not say the patient has to wait to be asked. The pattern in the British cases is that people reported the symptom, were switched to a drug in the same class, and lost months.

The clinical literature on gambling addiction is unambiguous that medication-induced cases tend to resolve when the offending drug is withdrawn rather than rotated. And the reason this belongs in an addiction publication rather than a neurology one is that the people who arrive in treatment for a gambling disorder are rarely asked what they are taking — which means a case that a pharmacy label could explain in one line gets treated for years as a primary behavioral problem, sometimes alongside the dual diagnosis care that the underlying illness genuinely requires.

Four drugs. One class effect. A warning that has been in print for a quarter of a century, and a review step that still depends on somebody remembering to ask.